Kadimastem Ltd

Equities

KDST

IL0011284614

Biotechnology & Medical Research

Market Closed - TEL AVIV STOCK EXCHANGE 13:49:24 21/04/2024 BST 5-day change 1st Jan Change
469.9 ILa +1.80% Intraday chart for Kadimastem Ltd -3.51% -20.76%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Kadimastem Ltd Reports Earnings Results for the Full Year Ended December 31, 2023 CI
IMC Announces Potential Reverse Merger With A Leading Clinical Cell Therapy Company MT
Kadimastem Ltd entered into a non-binding term sheet to acquire IM Cannabis Corp. in reverse merger transaction. CI
Kadimastem Plans Listing on Nasdaq Through Merger CI
ITolerance, Inc. and Kadimastem Ltd. Submit Initial Targeted Engagement for Regulatory Advice on CBER Products CI
Kadimastem Ltd announced that it expects to receive ILS 6.783 million in funding from Alpha Capital Anstalt and another investor CI
Kadimastem Ltd Reports Earnings Results for the Half Year Ended June 30, 2023 CI
Kadimastem Ltd announced that it expects to receive ILS 3.53 million in funding CI
Kadimastem to Launch Clinical Trial in ALS Patients Upon Approval from the Hadassah Hospital IRB CI
Kadimastem Receives Approval from the IRB (Helsinki Committee) of the Hadassah Ein Kerem Hospital for the Phase 1/2A Clinical Trial in Als Patients CI
Kadimastem Ltd announced that it expects to receive ILS 2.13 million in funding CI
Kadimastem Ltd. Announces Resignation of Eynat Tsafrir, Independent Director CI
Kadimastem Ltd announced that it expects to receive ILS 1 million in funding CI
Kadimastem Announces Granting a Patent in the US for Treatment of Neurodegenerative Diseases CI
Kadimastem Ltd. announced that it expects to receive ILS 2.7 million in funding CI
Kadimastem Ltd. announced that it expects to receive ILS 2.5 million in funding CI
Chart Kadimastem Ltd
More charts
Kadimastem Ltd is an Israel-based regenerative medicine company focused on the industrial development and commercialization of stem cell-based therapeutics, primarily for diabetes and neurodegenerative disorders. The Company’s technology enables the differentiation of stem cells into insulin secreting beta cells, as well as a range of neural cells (including Oligodendrocytes, Astrocytes). The Company produces islet-like clusters that show glucose-stimulated insulin secretion. In addition, the Company is partnering with pharmaceutical companies interested to screen potential drug compounds (hit-lead, lead optimization) on its stem-cell derived cells, primarily oligodendrocytes and astrocytes.
More about the company
  1. Stock Market
  2. Equities
  3. KDST Stock
  4. News Kadimastem Ltd
  5. IMC Announces Potential Reverse Merger With A Leading Clinical Cell Therapy Company